
InfraTrac
InfraTrac´s that needs tracking and anti-counterfeiting measures, including gasoline, plastics, fabrics, computer components, and paint.
Date | Investors | Amount | Round |
---|---|---|---|
- | investor investor investor | €0.0 | round |
investor investor | €0.0 | round | |
N/A | €0.0 | round | |
N/A | €0.0 | round | |
* | $400k | Grant | |
Total Funding | 000k |
Related Content
InfraTrac, founded in 2006 by Dr. Sharon Flank, operates as a specialized technology firm focused on cyber-physical security solutions to combat counterfeiting. Dr. Flank, the company's CEO, brings a multi-decade career in high-tech, having previously managed scientists and engineers at SRA International and served as CTO of eMotion, Inc. Her background in commercializing technology and intellectual property, including holding ten patents herself, laid the groundwork for InfraTrac's business.
The company's core business involves providing chemical fingerprinting technology that protects physical goods from unauthorized replication. The business model centers on licensing its patented technology and providing solutions to high-value industries where authenticity is critical, such as aerospace, defense, and pharmaceuticals. InfraTrac generates revenue through contracts and has successfully secured venture backing from TEDCO and over $1 million in Small Business Innovation Research (SBIR) funding from government bodies like the National Institutes of Health (NIH) and the National Institute of Science and Technology (NIST).
InfraTrac’s primary service is a patented anti-counterfeiting technology that embeds a covert chemical taggant within a product, which can be authenticated instantly using a pocket-sized spectrometer. For the additive manufacturing sector, this involves placing secure taggants within the layers of a 3D-printed object, making it possible to verify the part's origin and authenticity. This is particularly crucial for clients like Lockheed Martin, which has awarded InfraTrac multiple contracts for quality and authentication in its 3D printing processes. In the pharmaceutical space, the company offers patented in-dose fingerprinting, which involves minuscule, spectroscopically detectable alterations to inactive ingredients in powders and pills, falling within FDA guidelines that do not require re-approval. This allows for the tracking of individual batches and the detection of black or gray market products.
Keywords: anti-counterfeiting, chemical fingerprinting, additive manufacturing security, supply chain security, spectroscopic authentication, in-dose fingerprinting, brand protection, 3D printing validation, cyber-physical security, taggant technology